Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with bone erosion

doi:10.3969/j.issn.1006-7795.2019.06.004

Abstract

Abstract: Objective To explore the relationship between the anti-cyclic citrullinated peptide (ACCP) antibody and bone erosion in patients with rheumatoid arthritis (RA). Methods One hundred and one RA patients were enrolled. Eighty-one of these patients were female, and 75 cases were ACCP positive. Gray scale (GS) and power Doppler (PD) ultrasound was performed to assess bone erosion, synovial hypertrophy, and PD signal. The bilateral wrists, I-V metacarpophalangeal joints, Ⅱ-Ⅲ metacarpophalangeal joints of the hands were detected by GS and PD ultrasound. Appropriate statistical analysis methods were used to analyze the difference of ultrasonographic characteristics in ACCP-positive and ACCP-negative patients, and explore the relationship of the ACCP antibody, disease duration with bone erosion. Results Bone erosion score in ACCP-positive patients was significantly greater than in ACCP-negative patients (P=0.009). No statistically significant difference was observed in synovial hypertrophy and PD signal between ACCP-positive patients and ACCP-negative patients. In RA patients with a disease duration >3 years, however, bone erosion score in ACCP-positive patients was significantly greater than that in ACCP-negative patients (P=0.01). Conclusion ACCP-positive RA patients with a disease duration >3 years had higher bone erosion score.

Key words: rheumatoid arthritis, anti-cyclic citrullinated peptide antibody, ultrasonography, bone erosion

CLC Number:

Li Wenxue, Liu Fang, Zhu Jiaan, Liu Fang, Chen Zheng, Li Diancheng. Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with bone erosion[J]. Journal of Capital Medical University, 2019, 40(6): 829-832.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2019.06.004

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2019/V40/I6/829

References

[1] Smolen J S, Aletaha D, Mclinnes I B. Rheumatoid arthritis[J]. Lancet,2016, 388(10055):2023-2038.
[2] Aletaha D, Neogi T, Silman A J, et al. 2010 rheumatoid arthritis classification criteria:an American college of rheumatology/european league against rheumatism collaborative initiative[J]. Ann Rheum Dis, 2010, 69(9):1580-1588.
[3] Sulaiman F N, Wong K K, Ahmad W A W, et al. Anti-cyclic citrullinated peptide antibody is highly associated with rheumatoid factor and radiological defects in rheumatoid arthritis patients[J]. Medicine(Baltimore), 2019, 98(12):e14945.
[4] Szkudlarek M, Klarlund M, Narvestad E, et al. Ultrasonography of the metacarpophalangeal and proximal interphalangeal joints in rheumatoid arthritis:a comparison with magnetic resonance imaging, conventional radiography and clinical examination[J]. Arthritis Res Ther, 2006, 8(2):R52.
[5] Ten Cate D F, Jacobs J W G, Swen W A A, et al. Can baseline ultrasound results help to predict failure to achieve DAS28 remission after 1 year of tight control treatment in early RA patients?[J]. Arthritis Res Ther, 2018, 20(1):15.
[6] 中国医师协会超声医师分会, 中国肌骨超声检查指南[M]. 北京:人民卫生出版社, 2017.
[7] Myasoedova E, Crowson C S, Kremers H M, et al. Is the incidence of rheumatoid arthritis rising?:results from olmsted county, minnesota, 1955-2007[J]. Arthritis Rheum, 2010, 62(6):1576-1582.
[8] 饶志华, 曾光.硫酸羟氯喹联合甲氨蝶呤与来氟米特治疗类风湿关节炎临床疗效分析[J].中国煤炭工业医学杂志,2018,21(2):118-121.
[9] Gadeholt O, Wech T, Schuh S, et al. Anti-CCP status determines the power doppler oscillation pattern in rheumatoid arthritis:a prospective study[J]. Rheumatol Int, 2016, 36(12):1671-1675.
[10] van der Helm-van Mil A H, Verpoort K N, Breedveld F C, et al. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis[J]. Arthritis Res Ther, 2005, 7(5):R949-R958.
[11] Fedele A L, Petricca L, Tolusso B, et al. Interleukin-6 and IgA-rheumatoid factor are crucial for baseline erosiveness, and anti-citrullinated peptide antibodies for radiographic progression in early rheumatoid arthritis treated according to a treat-to-target strategy[J]. Scand J Rheumatol, 2018, 47(5):351-359.
[12] Hetland M L, Stengaard-Pedersen K, Junker P, et al. Radiographic progression and remission rates in early rheumatoid arthritis-MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial[J]. Ann Rheum Dis, 2010, 69(10):1789-1795.
[13] Breedveld F C, Weisman M H, Kavanaugh A F, et al. The PREMIER study:A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment[J]. Arthritis Rheum, 2006, 54(1):26-37.
[14] Ohmura K, Terao C, Maruya E, et al. Anti-citrullinated peptide antibody-negative RA is a genetically distinct subset:a definitive study using only bone-erosive ACPA-negative rheumatoid arthritis[J]. Rheumatology(Oxford), 2010, 49(12):2298-2304.
[15] Archer R, Hock E, Hamilton J, et al. Assessing prognosis and prediction of treatment response in early rheumatoid arthritis:systematic reviews[J]. Health Technol Assess, 2018, 22(66):1-294.